VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totaling 18,491 shares, a decline of 16.5% from the November 30th total of 22,133 shares. Based on an average daily trading volume, of 7,132 shares, the days-to-cover ratio is currently 2.6 days. Currently, 0.9% of the company’s shares are sold short. Currently, 0.9% of the company’s shares are sold short. Based on an average daily trading volume, of 7,132 shares, the days-to-cover ratio is currently 2.6 days.

VanEck Biotech ETF Price Performance

BBH opened at $189.30 on Friday. The stock’s 50-day moving average price is $188.88 and its 200 day moving average price is $172.63. VanEck Biotech ETF has a 12-month low of $135.34 and a 12-month high of $198.08.

VanEck Biotech ETF Dividend Announcement

The firm also recently declared an annual dividend, which was paid on Friday, December 26th. Stockholders of record on Monday, December 22nd were given a dividend of $0.9565 per share. This represents a dividend yield of 50.0%. The ex-dividend date of this dividend was Monday, December 22nd.

Institutional Investors Weigh In On VanEck Biotech ETF

Large investors have recently added to or reduced their stakes in the business. Strategic Financial Services Inc. acquired a new position in shares of VanEck Biotech ETF in the first quarter worth $203,000. EWG Elevate Inc. purchased a new position in VanEck Biotech ETF in the second quarter valued at $363,000. Bleakley Financial Group LLC purchased a new position in VanEck Biotech ETF in the second quarter valued at $2,909,000. Ameritas Advisory Services LLC acquired a new position in VanEck Biotech ETF during the 2nd quarter worth $57,000. Finally, Jones Financial Companies Lllp increased its holdings in VanEck Biotech ETF by 5,710.9% during the 1st quarter. Jones Financial Companies Lllp now owns 152,070 shares of the company’s stock worth $23,925,000 after purchasing an additional 149,453 shares during the period. 32.05% of the stock is owned by hedge funds and other institutional investors.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.